|
|
|
|
| LEADER |
01604nam a2200493Ia 4500 |
| 001 |
10-1016-j-annonc-2021-11-012 |
| 008 |
220420s2022 CNT 000 0 und d |
| 020 |
|
|
|a 09237534 (ISSN)
|
| 245 |
1 |
0 |
|a Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
| 260 |
|
0 |
|b Elsevier Ltd
|c 2022
|
| 300 |
|
|
|a 15
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1016/j.annonc.2021.11.012
|
| 650 |
0 |
4 |
|a antibody conjugate
|
| 650 |
0 |
4 |
|a antibody drug conjugates
|
| 650 |
0 |
4 |
|a bladder cancer
|
| 650 |
0 |
4 |
|a bladder tumor
|
| 650 |
0 |
4 |
|a Carcinoma, Transitional Cell
|
| 650 |
0 |
4 |
|a fibroblast growth factor receptor inhibitors
|
| 650 |
0 |
4 |
|a follow up
|
| 650 |
0 |
4 |
|a Follow-Up Studies
|
| 650 |
0 |
4 |
|a human
|
| 650 |
0 |
4 |
|a Humans
|
| 650 |
0 |
4 |
|a immune checkpoint inhibitors
|
| 650 |
0 |
4 |
|a Immunoconjugates
|
| 650 |
0 |
4 |
|a platinum-based chemotherapy
|
| 650 |
0 |
4 |
|a practice guideline
|
| 650 |
0 |
4 |
|a transitional cell carcinoma
|
| 650 |
0 |
4 |
|a Urinary Bladder Neoplasms
|
| 650 |
0 |
4 |
|a urothelial carcinoma
|
| 700 |
1 |
0 |
|a Bellmunt, J.
|e author
|
| 700 |
1 |
0 |
|a Comperat, E.
|e author
|
| 700 |
1 |
0 |
|a De Santis, M.
|e author
|
| 700 |
1 |
0 |
|a ESMO Guidelines Committee
|e author
|
| 700 |
1 |
0 |
|a Gillessen, S.
|e author
|
| 700 |
1 |
0 |
|a Huddart, R.
|e author
|
| 700 |
1 |
0 |
|a Loriot, Y.
|e author
|
| 700 |
1 |
0 |
|a Necchi, A.
|e author
|
| 700 |
1 |
0 |
|a Powles, T.
|e author
|
| 700 |
1 |
0 |
|a Ravaud, A.
|e author
|
| 700 |
1 |
0 |
|a Shariat, S.F.
|e author
|
| 700 |
1 |
0 |
|a Szabados, B.
|e author
|
| 700 |
1 |
0 |
|a Valderrama, B.P.
|e author
|
| 700 |
1 |
0 |
|a van der Heijden, M.S.
|e author
|
| 773 |
|
|
|t Annals of Oncology
|
